31 August 2017 - Yesterday’s historic FDA approval of the first engineered T-cell treatment for cancer, Novartis’ Kymriah (tisagenlecleucel), was accompanied by inevitable questions about how the product would be priced. 

In the end, Novartis set the price at $475,000, which was lower than many analysts had predicted, considering the treatment is designed to cure some forms of acute lymphoblastic leukaemia—and in clinical trials it did just that for most patients.

How many $475,000 cures can the American health care system afford? And can insurers, drug developers and health providers work together to develop innovative payment systems that promote practice patterns that are both cost-effective for providers and lifesaving for patients?

Read Forbes article